Triglav Investments D.O.O. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 40.5% in the 1st quarter, HoldingsChannel.com reports. The firm owned 113,518 shares of the company’s stock after purchasing an additional 32,700 shares during the quarter. Johnson & Johnson comprises approximately 1.9% of Triglav Investments D.O.O.’s portfolio, making the stock its 16th biggest position. Triglav Investments D.O.O.’s holdings in Johnson & Johnson were worth $27,748,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in JNJ. J. Safra Sarasin Holding AG grew its stake in Johnson & Johnson by 0.6% during the 1st quarter. J. Safra Sarasin Holding AG now owns 481,585 shares of the company’s stock worth $117,669,000 after buying an additional 2,782 shares during the last quarter. Hibernia Wealth Partners LLC raised its stake in Johnson & Johnson by 25.4% in the first quarter. Hibernia Wealth Partners LLC now owns 1,683 shares of the company’s stock valued at $411,000 after buying an additional 341 shares during the last quarter. Lifeworks Advisors LLC boosted its holdings in Johnson & Johnson by 1.4% in the first quarter. Lifeworks Advisors LLC now owns 36,895 shares of the company’s stock worth $9,019,000 after acquiring an additional 520 shares in the last quarter. Avion Wealth grew its stake in shares of Johnson & Johnson by 68.5% during the first quarter. Avion Wealth now owns 1,586 shares of the company’s stock worth $387,000 after acquiring an additional 645 shares during the last quarter. Finally, LGT Fund Management Co Ltd. increased its holdings in shares of Johnson & Johnson by 770.7% during the first quarter. LGT Fund Management Co Ltd. now owns 112,310 shares of the company’s stock valued at $27,453,000 after acquiring an additional 99,411 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson News Summary
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Analysts expect Johnson & Johnson to post a solid Q2 print, with commentary pointing to an upbeat report even as Stelara faces headwinds. Johnson & Johnson: Analysts see upbeat Q2 print despite Stelara headwinds
- Positive Sentiment: Several preview pieces say JNJ is trading near all-time highs and could still have more upside if earnings and guidance come in strong. Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282
- Positive Sentiment: RBC raised its price target on JNJ to $287 from $265 and maintained an outperform rating, reinforcing bullish sentiment.
- Positive Sentiment: Coverage also highlighted JNJ’s strong year-to-date run and defensive healthcare appeal, which has supported investor demand ahead of earnings. Johnson & Johnson Reports Q2 Earnings Tomorrow. What Investors Should Expect.
- Neutral Sentiment: Other articles focused on JNJ as a dividend and income stock, which may support valuation but did not add new material catalysts. How to earn $500 a month from Johnson & Johnson stock ahead of Q2 earnings
- Negative Sentiment: Some commentary noted the stock’s rich valuation after a big rally, suggesting investors may be paying a premium heading into the report. What Lilly’s Peer-Beating Numbers Cost You
Johnson & Johnson Stock Down 1.6%
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.77 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.58 EPS for the current year.
Insider Activity
In related news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
JNJ has been the subject of several research analyst reports. Johnson Rice set a $270.00 price objective on shares of Johnson & Johnson in a research report on Friday, June 26th. Raymond James Financial boosted their target price on shares of Johnson & Johnson from $237.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Citigroup raised their price target on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Barclays lifted their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 15th. Finally, Guggenheim boosted their price objective on shares of Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a report on Friday, June 26th. Twenty investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $261.26.
Get Our Latest Stock Report on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
